Knight Therapeutics Inc.
GUD.TO
Price:
$6
Market Cap:
$599.20M
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for ...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2014-03-03
Stock Exchange
TSX
Ticker
GUD.TO
PE Ratio
[-150.00]
ROE
[-0.45%]
Current Ratio
[2.62]
Dividend Yield
[0%]
Enterprise Value
[623.56M]
Dividend History
The ROE as of December 2025 (TTM) for Knight Therapeutics Inc. (GUD.TO) is -0.45%
According to Knight Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -0.45%. This represents a change of 242.00% compared to the average of -0.13% of the last 4 quarters.
Knight Therapeutics Inc. (GUD.TO) Historical ROE (quarterly & annually)
How has GUD.TO ROE performed in the past?
The mean historical ROE of Knight Therapeutics Inc. over the last ten years is 1.32%. The current -0.45% ROE has changed -133.92% with respect to the historical average. Over the past ten years (40 quarters), GUD.TO's ROE was at its highest in in the June 2021 quarter at 3.26%. The ROE was at its lowest in in the December 2023 quarter at -3.26%.
Average
1.32%
Median
1.83%
Minimum
-3.62%
Maximum
5.32%
Knight Therapeutics Inc. (GUD.TO) ROE by Quarter and Year
Discovering the peaks and valleys of Knight Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 100.14%
Maximum Annual ROE = 5.32%
Minimum Annual Increase = -294.43%
Minimum Annual ROE = -3.62%
| Year | ROE | Change |
|---|---|---|
| 2024 | 0.54% | -124.17% |
| 2023 | -2.25% | -37.72% |
| 2022 | -3.62% | -294.43% |
| 2021 | 1.86% | -48.05% |
| 2020 | 3.58% | 100.14% |
| 2019 | 1.79% | -23.40% |
| 2018 | 2.34% | 34.37% |
| 2017 | 1.74% | -8.17% |
| 2016 | 1.89% | -64.40% |
| 2015 | 5.32% | -79.75% |
Knight Therapeutics Inc. (GUD.TO) Average ROE
How has GUD.TO ROE performed in the past?
The current ROE of Knight Therapeutics Inc. (GUD.TO) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-1.78%
5-year avg
0.02%
10-year avg
1.32%
Knight Therapeutics Inc. (GUD.TO) ROE vs. Peers
How is GUD.TO’s ROE compared to its peers?
Knight Therapeutics Inc.’s ROE is greater than Cresco Labs Inc. (-11.54%), less than Cipher Pharmaceuticals Inc. (16.11%), less than Vitalhub Corp. (3.12%), greater than Verano Holdings Corp. (-29.26%), less than Aurora Cannabis Inc. (12.55%), greater than Canopy Growth Corporation (-98.69%), less than Kneat.com, Inc. (0.83%), greater than TerrAscend Corp. (-87.14%), greater than OrganiGram Holdings Inc. (-6.84%), greater than Bright Minds Biosciences Inc. (-20.87%),
| Company | ROE | Market cap |
|---|---|---|
| -11.54% | $599.26M | |
| 16.11% | $372.68M | |
| 3.12% | $515.09M | |
| -29.26% | $622.32M | |
| 12.55% | $387.54M | |
| -98.69% | $370.75M | |
| 0.83% | $464.03M | |
| -87.14% | $336.03M | |
| -6.84% | $371.11M | |
| -20.87% | $821.86M |
Build a custom stock screener for Knight Therapeutics Inc. (GUD.TO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Knight Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Knight Therapeutics Inc. (GUD.TO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Knight Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Knight Therapeutics Inc.'s ROE?
How is the ROE calculated for Knight Therapeutics Inc. (GUD.TO)?
What is the highest ROE for Knight Therapeutics Inc. (GUD.TO)?
What is the 3-year average ROE for Knight Therapeutics Inc. (GUD.TO)?
What is the 5-year average ROE for Knight Therapeutics Inc. (GUD.TO)?
How does the current ROE for Knight Therapeutics Inc. (GUD.TO) compare to its historical average?